STOCK TITAN

VCXBWS - VCXBWS STOCK NEWS

Welcome to our dedicated news page for VCXBWS (Ticker: VCXBWS), a resource for investors and traders seeking the latest updates and insights on VCXBWS.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VCXBWS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VCXBWS's position in the market.

Rhea-AI Summary
10X Capital Venture Acquisition Corp. III (VCXB) received a notice from NYSE Regulation for non-compliance with Section 1003(b)(i) of the NYSE American LLC Company Guide due to having fewer than 300 public shareholders. The company has until February 28, 2024, to submit a plan to regain compliance or face suspension and delisting procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
10X Capital Venture Acquisition Corp. III (VCXB) expects leadership changes with David Weisburd set to become the new CEO and Osman Ahmed as the new President, subject to board approval. Hans Thomas will remain as Chairman of the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) received a notice from NYSE American for not timely filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. The company's independent registered public accounting firm required additional time to complete the review of financial statements. However, 10X III subsequently cured its non-compliance by filing the Quarterly Report on November 27, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
Rhea-AI Summary
10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U, VCXB, VCXB WS) is transferring the listing of its Class A Ordinary Shares, Warrants, and Units from NYSE to NYSE American. The transfer is motivated by more favorable thresholds for continued listing. Trading on NYSE will end on October 6, 2023, and trading on NYSE American will commence on October 9, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
American Gene Technologies International Inc. (AGT) and 10X Capital Venture Acquisition Corp. III (VCXB) announced a merger agreement to form Addimmune, a publicly listed company focused on developing a functional cure for HIV. The investigational cell therapy, AGT103-T, has shown positive safety results in Phase I trials and will be targeted towards the 38 million people living with HIV globally. The proposed transaction represents a pre-money enterprise value of $500 million for Addimmune, with an additional earnout of up to $300 million tied to clinical and priced-based milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
acquisition
-
Rhea-AI Summary
American Gene Technologies International Inc. (AGT) and 10X Capital Venture Acquisition Corp. III (VCXB) announced a merger agreement to form Addimmune, a publicly listed company focused on developing a functional cure for HIV. The investigational cell therapy, AGT103-T, has shown positive safety results in Phase I trials and will be targeted towards the 38 million people living with HIV globally. The proposed transaction represents a pre-money enterprise value of $500 million for Addimmune, with an additional earnout of up to $300 million tied to clinical and priced-based milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
acquisition
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
IPO offering acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
IPO offering acquisition
VCXBWS

NYSE:VCXBWS

VCXBWS Rankings

VCXBWS Stock Data